FDB in $300m expansion of US single-use facility

Fujifilm Diosynth Biotechnologies (FDB) will make the most of $300m (€265m) to add a recent very good producing observe (cGMP) production facility to its Texas-located, US web page. The most current expenditure in the locale will double the company’s state-of-the-art remedy and vaccine manufacturing potential in the US.

The facility is envisioned to be operational by 2024 and will incorporate 138,000-square-feet to the current internet site, contributing to a overall house of 300,000-square-feet at the place.

By incorporating the facility, Fujifilm Diosynth expects to generate 150 positions in producing and operations by 2024.

Fujifilm Corporation’s investment decision in the web-site is component of a world initiative to extend its subsidiary’s capabilities, which saw a further create-out in the US to double its mobile tradition capacity​​, as very well as greatly expand solutions at its United kingdom website.

Enlargement plans

In terms of what products will be additional by the facility, the firm stated that it would household ‘multiple 500L and 2,000L bioreactors’, along with purification tools.

When requested, a spokesperson for Fujifilm Diosynth did not specify what the overall ability of the new website would be, other than doubling its existing functionality. Nevertheless, the Texas web page is already equipped to claim to be the largest solitary-use agreement improvement and manufacturing group (CDMO) creation campus in North America.

According to the spokesperson, the company is investing in ability in state-of-the-art therapies and vaccines, simply because “tomorrow’s medications might be desired incredibly quickly. We have noticed this with COVID at a huge worldwide scale.”